“…The diagnostic techniques for the cardiac myxoma were described in 34 (66.7%) patients, by transthoracic echocardiography in 26 (70%) [ 2 , 8 - 13 , 17 , 20 , 21 , 24 , 27 - 29 , 33 - 35 , 38 , 40 , 42 , 43 , 45 , 47 , 48 , 50 ] , transthoracic and transesophageal echocardiography in 4 (13.3%) [ 15 , 27 , 30 , 32 ] , transesophageal echocardiography in 2 (6.7%) [ 36 , 41 ] , cardiac catheterization [ 14 ] and a battery of tests [ 46 ] in 1 (3.3%) patient.…”
Section: Resultsmentioning
confidence: 99%
“…The dimensions of the cardiac myxomas were available in 25 (49.0%) patients. One of them was described as "egg-sized" [ 46 ] and average dimension of the remaining 24 myxomas was 55.1±24.5 (range, 22-130; median, 55) mm ( n =24) [ 2 , 8 , 9 , 11 , 12 - 15 , 20 , 21 , 23 , 26 , 27 , 29 , 30 , 32 , 35 , 39 , 42 , 43 , 47 ] .…”
Section: Resultsmentioning
confidence: 99%
“…Concerning the remaining 49 patients, surgical operation was not performed in 2 (4.1%) patients but with anticoagulant and antibiotic therapy in one [ 36 ] and decline of treatment by another [ 41 ] . A surgical resection of cardiac myxoma was performed in 47 (95.9%) patients including a sole cardiac myxoma resection in 41 (87.2%) [ 2 , 8 - 21 , 23 - 27 , 29 , 31 - 39 , 43 - 46 , 48 - 50 ] , concurrent mitral valve repair [ 40 , 47 ] and staged mitral valve replacement [ 28 , 29 ] in 2 (4.3%), and staged mitral valve repair [ 30 ] and concurrent patent fossa ovalis closure [ 42 ] in 1 (2.1%) patient. Cardiac surgery was performed in the first, second and third trimester in 5 (13.9%), 14 (38.9%) and 17 (47.2%) patients ( χ 2 =9.8, P =0.008) at a mean of 25.2±9.4 (range, 9-41; median 27) weeks of gestational age ( n =36); while timing of cardiac surgery was not given in 15 (29.4%) patients.…”
Section: Resultsmentioning
confidence: 99%
“…A cardiac myxoma resection was delayed in 4 (7.8%) patients for a few [ 43 ] , 7 [ 21 ] , 15 [ 40 ] and 690 days [ 13 ] , respectively. The feto-neonatal fate was not mentioned in 13 (25.5%) cases [ 15 , 22 , 24 , 27 , 31 , 37 , 38 , 41 , 44 , 47 ] . Voluntary termination of pregnancy was done in 7 (13.7%) cases with 6 (85.7%) early-mid-termed [ 2 , 9 , 12 , 23 , 42 ] and 1 (14.3%) late pregnancy termination [ 50 ] with mean gestational age of 17.0±8.3 (range, 11-31; median, 14) weeks ( n =5).…”
ObjectiveCardiac myxoma in pregnancy is rare and the clinical characteristics of this
entity have been insufficiently elucidated. This article aims to describe the
treatment options and the risk factors responsible for the maternal and
feto-neonatal prognoses.MethodsA comprehensive search of the literature of cardiac myxoma in pregnancy was
conducted and 44 articles with 51 patients were included in the present
review.ResultsTransthoracic echocardiography was the most common diagnostic tool for the
diagnosis of cardiac myxoma during pregnancy. Cardiac myxoma resection was
performed in 95.9% (47/49); while no surgical resection was performed in 4.1%
(2/49) patients (P=0.000). More patients had an isolated cardiac
myxoma resection in comparison to those with a concurrent or staged additional
cardiac operation [87.2% (41/47) vs. 12.8% (6/47),
P=0.000]. A voluntary termination of the pregnancy was
done in 7 (13.7%) cases. In the remaining 31 (60.8%) pregnant patients, cesarean
section was the most common delivery mode representing 61.3% and vaginal delivery
was more common accounting for 19.4%. Cardiac surgery was performed in the first,
second and third trimester in 5 (13.9%), 14 (38.9%) and 17 (47.2%) patients,
respectively. No patients died. In the delivery group, 20 (76.9%) neonates were
event-free survivals, 4 (15.4%) were complicated and 2 (7.7%) died. Neonatal
prognoses did not differ between the delivery modes, treatment options, timing of
cardiac surgery and sequence of cardiac myxoma resection in relation to
delivery.ConclusionThe diagnosis of cardiac myxoma in pregnancy is important. Surgical treatment of
cardiac myxoma in the pregnant patients has brought about favorable maternal and
feto-neonatal outcomes in the delivery group, which might be attributable to the
shorter operation duration and non-emergency nature of the surgical intervention.
Proper timing of cardiac surgery and improved cardiopulmonary bypass conditions
may result in even better maternal and feto-neonatal survivals.
“…The diagnostic techniques for the cardiac myxoma were described in 34 (66.7%) patients, by transthoracic echocardiography in 26 (70%) [ 2 , 8 - 13 , 17 , 20 , 21 , 24 , 27 - 29 , 33 - 35 , 38 , 40 , 42 , 43 , 45 , 47 , 48 , 50 ] , transthoracic and transesophageal echocardiography in 4 (13.3%) [ 15 , 27 , 30 , 32 ] , transesophageal echocardiography in 2 (6.7%) [ 36 , 41 ] , cardiac catheterization [ 14 ] and a battery of tests [ 46 ] in 1 (3.3%) patient.…”
Section: Resultsmentioning
confidence: 99%
“…The dimensions of the cardiac myxomas were available in 25 (49.0%) patients. One of them was described as "egg-sized" [ 46 ] and average dimension of the remaining 24 myxomas was 55.1±24.5 (range, 22-130; median, 55) mm ( n =24) [ 2 , 8 , 9 , 11 , 12 - 15 , 20 , 21 , 23 , 26 , 27 , 29 , 30 , 32 , 35 , 39 , 42 , 43 , 47 ] .…”
Section: Resultsmentioning
confidence: 99%
“…Concerning the remaining 49 patients, surgical operation was not performed in 2 (4.1%) patients but with anticoagulant and antibiotic therapy in one [ 36 ] and decline of treatment by another [ 41 ] . A surgical resection of cardiac myxoma was performed in 47 (95.9%) patients including a sole cardiac myxoma resection in 41 (87.2%) [ 2 , 8 - 21 , 23 - 27 , 29 , 31 - 39 , 43 - 46 , 48 - 50 ] , concurrent mitral valve repair [ 40 , 47 ] and staged mitral valve replacement [ 28 , 29 ] in 2 (4.3%), and staged mitral valve repair [ 30 ] and concurrent patent fossa ovalis closure [ 42 ] in 1 (2.1%) patient. Cardiac surgery was performed in the first, second and third trimester in 5 (13.9%), 14 (38.9%) and 17 (47.2%) patients ( χ 2 =9.8, P =0.008) at a mean of 25.2±9.4 (range, 9-41; median 27) weeks of gestational age ( n =36); while timing of cardiac surgery was not given in 15 (29.4%) patients.…”
Section: Resultsmentioning
confidence: 99%
“…A cardiac myxoma resection was delayed in 4 (7.8%) patients for a few [ 43 ] , 7 [ 21 ] , 15 [ 40 ] and 690 days [ 13 ] , respectively. The feto-neonatal fate was not mentioned in 13 (25.5%) cases [ 15 , 22 , 24 , 27 , 31 , 37 , 38 , 41 , 44 , 47 ] . Voluntary termination of pregnancy was done in 7 (13.7%) cases with 6 (85.7%) early-mid-termed [ 2 , 9 , 12 , 23 , 42 ] and 1 (14.3%) late pregnancy termination [ 50 ] with mean gestational age of 17.0±8.3 (range, 11-31; median, 14) weeks ( n =5).…”
ObjectiveCardiac myxoma in pregnancy is rare and the clinical characteristics of this
entity have been insufficiently elucidated. This article aims to describe the
treatment options and the risk factors responsible for the maternal and
feto-neonatal prognoses.MethodsA comprehensive search of the literature of cardiac myxoma in pregnancy was
conducted and 44 articles with 51 patients were included in the present
review.ResultsTransthoracic echocardiography was the most common diagnostic tool for the
diagnosis of cardiac myxoma during pregnancy. Cardiac myxoma resection was
performed in 95.9% (47/49); while no surgical resection was performed in 4.1%
(2/49) patients (P=0.000). More patients had an isolated cardiac
myxoma resection in comparison to those with a concurrent or staged additional
cardiac operation [87.2% (41/47) vs. 12.8% (6/47),
P=0.000]. A voluntary termination of the pregnancy was
done in 7 (13.7%) cases. In the remaining 31 (60.8%) pregnant patients, cesarean
section was the most common delivery mode representing 61.3% and vaginal delivery
was more common accounting for 19.4%. Cardiac surgery was performed in the first,
second and third trimester in 5 (13.9%), 14 (38.9%) and 17 (47.2%) patients,
respectively. No patients died. In the delivery group, 20 (76.9%) neonates were
event-free survivals, 4 (15.4%) were complicated and 2 (7.7%) died. Neonatal
prognoses did not differ between the delivery modes, treatment options, timing of
cardiac surgery and sequence of cardiac myxoma resection in relation to
delivery.ConclusionThe diagnosis of cardiac myxoma in pregnancy is important. Surgical treatment of
cardiac myxoma in the pregnant patients has brought about favorable maternal and
feto-neonatal outcomes in the delivery group, which might be attributable to the
shorter operation duration and non-emergency nature of the surgical intervention.
Proper timing of cardiac surgery and improved cardiopulmonary bypass conditions
may result in even better maternal and feto-neonatal survivals.
“…According to one retrospective study of 153 atrial myxoma patients between 1993 and 2017, only one presented with haemoptysis 9. In addition, haemoptysis is regarded as a more common presentation of right atrial myxoma, most likely related to tumour embolus to the lung 10. Unusual clinical presentations of myxoma include presentation with lower limb paresthesia due to arterial embolisation11 as well as presentation with abdominal pain due to bowel ischaemia 12.…”
Cardiac myxomas are scarce and their clinical manifestations can often be misdiagnosed or confused with other medical conditions. However, early diagnosis and surgical resection can prevent devastating complications of myxomas.We herein describe a case of a huge left atrial myxoma of a female patient in her late 30s. What makes our case unique, apart from the massive size of the myxoma, is the unusual clinical presentation with incessant cough and haemoptysis for more than 6 months. The diagnosis was made by echocardiography and cardiac MR and successful surgical resection was performed with good long-term outcome.
Diagnosis of myxoma can be difficult given its variable presentation and while adopting common sense in diagnosing this condition, physicians should also be aware of atypical presentations. Herein we present a 47-year-old heavy smoker presented with massive blood-stained expectoration. He was later diagnosed with cardiac myxoma and managed accordingly.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.